Alicia Faulkner, NP
Adult Health · Houston, TXNPI 1114550621
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,128 of the $7,344 with a category attached, or 83.4%. 37 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 28.5% of the total. Among adult health clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$616
- Mylan Specialty L.p.$491
- Actelion Pharmaceuticals US, Inc.$270
- plus $2K from 31 others
What the payments were for
- Travel & lodging$1,21617%
- Food & beverage$6,12883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 40 | $2,090 |
| AstraZeneca | 40 | $1,170 |
| GSK | 61 | $1,092 |
| Regeneron Healthcare Solutions, Inc. | 29 | $616 |
| Mylan Specialty L.p. | 24 | $491 |
| Actelion Pharmaceuticals US, Inc. | 11 | $270 |
| Philips North America LLC | 16 | $267 |
| Inari Medical, Inc. | 14 | $221 |
| Tactile Systems Technology Inc | 3 | $105 |
| Sanofi | 5 | $104 |
| Azurity Pharmaceuticals, Inc. | 4 | $70 |
| Johnson & Johnson | 3 | $62 |
| United Therapeutics Corporation | 3 | $57 |
| Boehringer Ingelheim | 3 | $55 |
| Electromed, Inc. | 4 | $55 |
| Verona Pharma, Inc. | 3 | $55 |
| Bolton Medical Inc | 2 | $47 |
| Viatris Specialty LLC | 2 | $45 |
| Corcept Therapeutics | 2 | $45 |
| Insmed, Inc. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Novo Nordisk | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Abiomed | 1 | $25 |
| Baxter Healthcare | 1 | $25 |
| Bayer | 1 | $23 |
| Alcresta Therapeutics, Inc. | 1 | $23 |
| Cequr Corporation | 1 | $23 |
| Amgen | 1 | $23 |
| Pulmonx Corporation | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Gilead | 1 | $16 |
| Inogen, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$1,051
- Inspire$640
- BREZTRI$355
- NUCALA$119
How this compares
$7,344 in reported general payments places this provider in the 90th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $56,745 |
| Spiriva RespimatTiotropium Bromide | 11 | $10,344 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,665 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $5,788 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,103 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,088 |
| Fluticasone Propionate | 39 | $433 |
| Montelukast Sodium | 29 | $417 |
| Azithromycin | 20 | $118 |
| Prednisone | 31 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,092 | $62,533100 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $55 | $15,44622 claims |
| AstraZenecaBreztri Aerosphere | $1,170 | $9,66515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 adult health providers in Texas.
Other adult health in Houston
- Kacey LyonsHouston$20K
- Rosa RancesHouston$17K
- Claressa RosacinaHouston$17K
- Michelle MartinHouston$15K
- Loren SemonesHouston$14K
- Anthony SantosHouston$13K
- Dashawn ThomasHouston$11K
- Zandra RiveraHouston$11K
- Brandy KhodrHouston$10K
- Janice TranHouston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.